The protease mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) is a signaling protein with both molecular scaffolding and protease activity involved in lymphocyte activation. MALT1 is considered a therapeutic target for chronic lymphocytic leukemia (CLL) in patients who develop resistance to Bruton tyrosine kinase (BTK) inhibitors.
Hangzhou Sino-US Huadong Medicine Co. Ltd. and Synerk Pharmatech (Suzhou) Co. Ltd. have entered into a strategic collaboration in which the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726.
Due to its dual role in adaptive immune responses, modulation of endoplasmic reticulum aminopeptidase 1 (ERAP1) is considered a potential strategy to both boost cancer immunotherapies or reduce self-antigen generation in the context of autoimmune diseases.
Among the most profound results presented at the 2024 European Society for Medical Oncology (ESMO) Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials of Opdivo and Keytruda as first-line agents in advanced or metastatic melanoma in which 10-year overall survival topped 40%. The success of checkpoint blockade, however, has not extended to all tumor types, but in 2024, molecular studies have led to advances in gene therapies and a multitude of approaches that have opened the door to hope.
Casma Therapeutics Inc. has described autophagy targeting chimeras (AUTACs) comprising sequestosome-1 (ubiquitin-binding protein p62; SQSTM1) ligands coupled to an echinoderm microtubule-associated protein-like 4-ALK (EML4- ALK)-targeting moiety via a linker.
Centennial Therapeutics LLC has divulged ketohexokinase (KHK) inhibitors reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Revolution Medicines Inc. has synthesized macrocyclic compounds acting as GTPase KRAS, NRAS, HRAS and their mutant inhibitors reported to be useful for the treatment of cancer.
Samjin Pharmaceutical Co. Ltd. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer.
RSS
